Oncolytics Biotech Inc. (TSX:ONC)

Canada flag Canada · Delayed Price · Currency is CAD
0.7000
+0.0100 (1.43%)
May 7, 2025, 3:59 PM EDT
-56.25%
Market Cap 60.62M
Revenue (ttm) n/a
Net Income (ttm) -31.71M
Shares Out 86.60M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,925
Average Volume 56,934
Open 0.7100
Previous Close 0.7000
Day's Range 0.7000 - 0.7300
52-Week Range 0.6700 - 2.0800
Beta 1.51
RSI 39.34
Earnings Date May 7, 2025

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 28
Stock Exchange Toronto Stock Exchange
Ticker Symbol ONC
Full Company Profile

Financial Performance

Financial Statements

News

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-sta...

1 day ago - PRNewsWire

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest an...

13 days ago - PRNewsWire

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered ...

27 days ago - PRNewsWire

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discusse...

27 days ago - PRNewsWire

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

2 months ago - Benzinga

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

2 months ago - PRNewsWire

Oncolytics Biotech Q4 2024 Earnings Preview

2 months ago - Seeking Alpha

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a l...

2 months ago - PRNewsWire

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential...

2 months ago - PRNewsWire

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor typ...

2 months ago - PRNewsWire

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc...

2 months ago - PRNewsWire

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage comp...

3 months ago - Benzinga

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Search for Chief Executive Officer to commence immediately SAN DIEGO  and  CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage compa...

3 months ago - PRNewsWire

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

3 months ago - Benzinga

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

3 months ago - PRNewsWire

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB , Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), ...

4 months ago - PRNewsWire

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline unde...

4 months ago - PRNewsWire

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

SAN DIEGO  and CALGARY, AB , Dec. 18, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announ...

5 months ago - PRNewsWire

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with ...

5 months ago - PRNewsWire

Oncolytics Biotech GAAP EPS of -$0.12 misses by $0.04

Oncolytics Biotech misses Q3 earnings estimates by $0.04.

6 months ago - Seeking Alpha